BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified

BioMarin Pharmaceutical Inc. presented new efficacy data on its treatments POMBILITI (cipaglucosidase alfa-atga) and OPFOLDA (miglustat) for late-onset Pompe disease at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan. The company reported no new safety signals associated with the treatments.